Axovant Sciences (AXON) & Its Peers Head-To-Head Comparison

Axovant Sciences (NASDAQ: AXON) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Axovant Sciences to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, valuation, risk and earnings.

Profitability

This table compares Axovant Sciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Axovant Sciences N/A -146.93% -97.18%
Axovant Sciences Competitors -5,266.10% -428.13% -38.73%

Earnings and Valuation

This table compares Axovant Sciences and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Axovant Sciences N/A -$180.95 million -2.38
Axovant Sciences Competitors $284.30 million $34.29 million 135.48

Axovant Sciences’ peers have higher revenue and earnings than Axovant Sciences. Axovant Sciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Axovant Sciences and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axovant Sciences 2 3 6 0 2.36
Axovant Sciences Competitors 843 3191 11569 230 2.71

Axovant Sciences presently has a consensus target price of $14.68, suggesting a potential upside of 166.94%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.58%. Given Axovant Sciences’ higher possible upside, equities research analysts plainly believe Axovant Sciences is more favorable than its peers.

Insider & Institutional Ownership

96.9% of Axovant Sciences shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 72.4% of Axovant Sciences shares are held by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Axovant Sciences peers beat Axovant Sciences on 6 of the 11 factors compared.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company is focused to develop its lead product candidate, intepirdine, a selective 5-hydroxytryptamine 6 receptor antagonist, for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. The Company’s pipeline also includes RVT-103 and RVT-104.

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply